|
- Codexis, Inc. (CDXS)
Codexis offers scalable and efficient enzymatic processes for siRNA manufacturing With multiple enzymatic pathways to synthesize siRNA, you can choose the option that best meets your needs
- About Us :: Codexis, Inc. (CDXS)
Codexis is uniquely positioned to expand this development by providing enzymatically synthesized siRNA constructs Our siRNA is manufactured in an aqueous (water-based) solution, which drives down cost and avoids heavy use of toxic solvents
- Investors :: Codexis, Inc. (CDXS)
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes
- CodeEvolver® Platform :: Codexis, Inc. (CDXS)
Rapid Performance Improvements Our technology's unique combination of making larger improvements and having shorter cycle times per round allows us to advance enzyme performance by hundreds or thousands of folds while other technologies may only achieve a ten-fold improvement after a few iterative rounds in the same amount of time
- Services :: Codexis, Inc. (CDXS)
Codexis provides a wide range of siRNA manufacturing services using proprietary enzymatic technologies to synthesize your nucleic acid therapeutics for preclinical testing We can customize analytical methods, tailor final deliverable scales, and provide additional custom services to meet your needs
- News Events :: Codexis, Inc. (CDXS)
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
- FAQ :: Codexis, Inc. (CDXS)
Codexis Inc is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of
- Management Team :: Codexis, Inc. (CDXS)
As President CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1 9 billion
|
|
|